About
About Chr. Hansen Holding A/S
Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. The company operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products in the food industry, primarily in the dairy industry. The Health & Nutrition segment produces and sells products for the dietary supplement, over-the-counter pharmaceutical, infant formula, animal feed, and plant protection industries. It has a strategic collaboration with UPL Ltd. to develop and commercialize microbial-based bio solutions for sustainable agriculture. The company was founded in 1843 and is headquartered in Hørsholm, Denmark. As of January 29, 2024, Chr. Hansen Holding A/S operates as a subsidiary of Novozymes A/S.
Visit company website
5 years, 5 months ago
Chr. Hansen Holding A/S is currently in a long term downtrend where the price is trading 3.0% below its 200 day moving average.
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the Basic Materials sector with a price to sales ratio of 10.4.
Chr. Hansen Holding A/S's total revenue sank by 10.6% to $244M since the same quarter in the previous year.
Its net income has dropped by 17.0% to $41M since the same quarter in the previous year.
Finally, its free cash flow fell by 167.6% to $-19M since the same quarter in the previous year.
Based on the above factors, Chr. Hansen Holding A/S gets an overall score of 1/5.